Every time a headline demands that Prime Minister Andy Burnham slap an arbitrary national waiting-time target on dementia, the health policy establishment nods along in unison. Charities cheer. Campaigners issue glowing press releases. The narrative is irresistibly simple: set an 18-week cap, fund a cancer-style revolution, and watch administrative excellence cure the NHS.
It is also complete administrative malpractice.
I have watched hospitals blow millions on chasing bureaucratic metrics while actual clinical outcomes flatline. Bureaucrats love a target because a stopwatch is easy to audit. It gives politicians a soundbite for the evening news. But forcing memory clinics to rush complex neurodegenerative assessments into a rigid 18-week window is a brilliant way to manufacture diagnostic errors, burn out remaining specialists, and treat patients like serial numbers on a spreadsheet.
Stop treating cognitive decline like a broken leg.
The Fallacy of the Stopwatch in Cognitive Health
The lazy consensus argues that dementia diagnostic waits mirror elective surgery or oncology pathways. The logic goes: if you shorten the time between a GP referral and a confirmed diagnosis, you get people into treatment faster.
This premise collapses the moment it hits biological reality.
Cancer staging relies on fast biopsies and clear imaging to find malignant cells before they spread. Dementia is not a localized tumor. It is a slow, multi-system erosion of neural architecture. A proper differential diagnosis requires ruling out vitamin deficiencies, thyroid dysfunction, neurosyphilis, medication side effects, depression, and normal-pressure hydrocephalus. It requires detailed neuropsychological testing, informant histories, and increasingly, biomarker analysis or advanced neuroimaging.
When you impose a blunt 18-week clock on memory services that are already chronically understaffed, clinics do not magically conjure up thousands of trained old-age psychiatrists, neurologists, and specialized nurses. Instead, they resort to triage theater. They rush appointments. They hand out premature, low-confidence diagnoses to clear the queue, or conversely, they bounce complex cases back to GPs with generic rejection letters to stop the clock from expiring.
You do not help families by giving them a fast, wrong answer.
What the Charities Miss About Clinical Capacity
The Alzheimer’s Society and various advocacy groups point out that roughly a million people live with dementia in the UK, a figure projected to climb toward 1.4 million. They argue that a national standard will force the government to resource the sector adequately.
This is magical thinking disguised as activism.
Data from NHS providers shows that memory services are bottlenecked not by a lack of political willpower, but by a severe structural shortage of clinical talent. Mandating a target without first solving the workforce pipeline creates a zero-sum game. Clinicians are forced to choose between spending an hour conducting a thorough cognitive evaluation for a vulnerable patient or rushing through five appointments to satisfy a Whitehall Key Performance Indicator.
When targets become the primary metric of success, gaming the system becomes the primary occupation of management. We saw this play out with the four-hour A&E waiting standard. Hospitals parked ambulances outside for hours because checking a patient in would start a clock they couldn't afford to run. Applying that same blunt-instrument mentality to people losing their cognitive faculties is cruel.
The Dangerous Allure of Silver Bullet Drugs
Much of the current urgency is fueled by the arrival of disease-modifying therapies, such as lecanemab and other amyloid-targeting monoclonal antibodies. Campaigners argue that because these drugs exist, patients must be diagnosed instantly to qualify for them.
Let us look at the clinical trade-offs that the glossy brochures omit.
These new medications come with significant adverse effects, including amyloid-related imaging abnormalities (ARIA), which can involve brain swelling or microhemorrhages. They require rigorous, ongoing MRI monitoring, specialist infusion centers, and carefully selected patient profiles who are in the very earliest stages of mild cognitive impairment. They are not universal cures. They slow clinical decline by a modest margin in a carefully trial-screened subset of patients, at a massive cost to health service infrastructure.
If you force an 18-week diagnostic cap onto an unprepared system, you trigger a stampede of worried well patients demanding access to expensive, high-risk treatments. The clinics become overwhelmed with cognitive-test anxiety, crowding out the frail, late-stage patients and families who desperately need social care, psychological support, and community intervention.
What We Should Do Instead
If Andy Burnham wants to leave a lasting legacy on health and social care, he needs to abandon the comfort of vanity targets and focus on structural integration.
First, merge health and social care budgets at the hyper-local level. The greatest crisis facing dementia patients is not the length of time it takes to get a badge of diagnosis; it is the catastrophic financial cliff they fall off the day after they receive it. Families bear over sixty percent of the lifetime cost of dementia through means-tested social care charges that strip away life savings. Fixing social care protection from catastrophic loss matters infinitely more than hitting an arbitrary 18-week milestone.
Second, invest heavily in primary care upskilling. Rather than funneling every single person with age-related memory wobble into overburdened secondary care memory clinics, empower GPs and community geriatricians with accessible blood-based biomarker tests—such as plasma p-tau217—which are beginning to show real efficacy in ruling out Alzheimer pathology early on. Filter the noise at the source instead of building a longer traffic jam outside the hospital door.
Third, measure success by post-diagnostic continuity. A piece of paper naming a disease is worthless if it is handed to a family with no follow-up support, no Admiral Nurse access, and no respite care plan.
Targets are for politicians who want to pretend they are working. Systems are for patients who need to survive.
